L. Bernardo Menajovsky, MD, MS Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA
John Spandorfer, MD Jefferson Antithrombotic Therapy Service, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA
Address: L. Bernardo Menajovsky, MD, MS, Thomas Jefferson Thomas Jefferson University Hospital, 833 Chestnut Street East, Suite 701, Philadelphia, PA 19107; e-mail leon.menajovsky@jefferson.edu
Dr. Menajovsky has indicated that he is on the speakers’ bureau of the Aventis corporation.
Dr. Spandorfer has indicated that he has received grant or research support from the Aventis and Astra Zeneca corporations and is on the speakers’ bureaus of the Aventis and Astra Zeneca corporations.
This paper discusses therapies that are experimental or that are not approved by the US Food and Drug Administration for the use under discussion.
ABSTRACTVenous thromboembolism (VTE), which includes both deep vein thrombosis and pulmonary embolism, is a well-known risk in surgical patients, but it is also a significant and often unrecognized source of mortality and morbidity in hospitalized medical patients. The need for routine prophylaxis in the general medical population is increasingly supported.
